SynAct Pharma
SYNACT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008241491 (+1 more)
- LEI:
- 549300RRYIEFEQ72N546
- Country:
- Sweden
- Address:
- Scheelevägen 2, 223 63 Lund
- Website:
- https://synactpharma.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects, so that patients can achieve immune balance and live beyond their inflammation. AP1189, our product candidate selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression that is associated with most of the available anti-inflammatory therapies. These immunosuppressive approaches can lead to opportunistic infections and other serious side effects.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-13 10:18 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 10.6 KB | |
| 2025-06-04 08:50 |
Share Issue/Capital Change
SynAct Pharma AB genomför en riktad nyemission om 37 MSEK och förlänger sin fin…
|
Swedish | 77.4 KB | |
| 2025-06-04 08:50 |
Share Issue/Capital Change
SynAct Pharma AB carries out a directed share issue of SEK 37 million and exten…
|
English | 75.9 KB | |
| 2025-06-03 23:15 |
Capital/Financing Update
SynAct Pharma upptar en kreditfacilitet om 30 MSEK som förlänger bolagets finan…
|
Swedish | 66.6 KB | |
| 2025-06-03 23:15 |
Capital/Financing Update
SynAct Pharma takes out a credit facility of SEK 30 million that extends the co…
|
English | 66.1 KB | |
| 2025-05-27 11:05 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämma 2025 i SynAct Pharma AB
|
Swedish | 56.8 KB | |
| 2025-05-27 11:05 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from the annual general meeting 2025 in SynAct Pharma AB
|
English | 57.3 KB | |
| 2025-05-27 07:30 |
Interim Report
|
Swedish | 2.4 MB | |
| 2025-05-27 07:30 |
Interim Report
|
English | 2.4 MB | |
| 2025-05-22 10:11 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 10.5 KB | |
| 2025-05-20 10:00 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 10.5 KB | |
| 2025-05-15 10:32 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 10.5 KB | |
| 2025-04-24 16:00 |
Regulatory News Service
Notice of annual general meeting in SynAct Pharma AB
|
English | 91.4 KB | |
| 2025-04-24 16:00 |
Regulatory News Service
Kallelse till årsstämma i SynAct Pharma AB
|
Swedish | 91.6 KB | |
| 2025-03-10 10:16 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-02-24 | Henrik Stage | Other | Sell | 19,000 | 991,345.00 SEK |
| 2021-02-18 | John Haurum | Other | Sell | 5,968 | 328,749.67 SEK |
| 2021-01-06 | Thomas Jonassen | Other | Other | 1,456,263 | N/A |
| 2020-07-22 | Thomas Jonassen | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-10 | Jeppe Øvlesen | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-09 | John Haurum | Other | Other | 29,840 | 199,928.00 SEK |
| 2020-07-07 | Henrik Stage | Other | Other | 29,840 | 199,928.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |